Back to Search Start Over

Comparison of perventricular and percutaneous ultrasound-guided device closure of perimembranous ventricular septal defects.

Authors :
Huang LL
Chen M
Zeng C
Su CX
Jiang CL
Zheng BS
Wu J
Li SK
Source :
Frontiers in cardiovascular medicine [Front Cardiovasc Med] 2023 Nov 06; Vol. 10, pp. 1281860. Date of Electronic Publication: 2023 Nov 06 (Print Publication: 2023).
Publication Year :
2023

Abstract

Background: Ultrasound-guided percutaneous device closure of perimembranous ventricular septal defects (PmVSD) is a minimally invasive recent treatment approach. Perventricular PmVSD device closure is an emerging radiation-free intervention, yet it comes with certain limitations. No studies compared both of these treatment approaches.<br />Methods: We performed a retrospective institutional data comparison of percutaneous (PCP Group, n  = 138) and perventricular (PVP Group, n  = 67) ultrasound-guided device closure procedures in 205 patients with PmVSD between March 2017 and December 2022.<br />Results: Patients of the PCP and PVP groups had a median age of 4.9 years (IQR, 3.1-14.0) and 5.3 years (IQR, 3.4-13.1) respectively. The median PmVSD diameter in the PCP Group was 4.0 mm (IQR, 3.3-5.3) and 5.2 mm (IQR, 4.0-7.0) in the PVP Group ( p  = 0.001). There was no significant difference in success rates between the PCP and PVP Groups (intention-to-treat population, 88.4% vs. 92.5%, p  = 0.36; as-treated population, 88.4% vs. 89.3%, p  = 0.84). 5/8 failed percutaneous cases that were shifted to the perventricular approach were successful. Compared to the PVP Group, patients of the PCP group experienced a significant decrease in ventilation time, drainage volume, and postoperative hospital stay ( p  < 0.001). The median follow-up period was 24 months (IQR, 6-42) for the PCP group and 61 months (IQR, 53-65) for the PVP group. The overall severe adverse event rate was 0% in the PCP group and 3.0% in the PVP group.<br />Conclusions: Perventricular and percutaneous ultrasound-guided device closure of PmVSD are both effective and safe treatment options. The percutaneous approach offers less trauma and faster recovery and may be the preferred approach in selected patients.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (© 2023 Huang, Chen, Zeng, Su, Jiang, Zheng, Wu and Li.)

Details

Language :
English
ISSN :
2297-055X
Volume :
10
Database :
MEDLINE
Journal :
Frontiers in cardiovascular medicine
Publication Type :
Academic Journal
Accession number :
38028455
Full Text :
https://doi.org/10.3389/fcvm.2023.1281860